Prime Medicine
PRME • NASDAQ
Prime Medicine is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Allan Reine, with a market cap of $610.3M.
CEOAllan Reine
Next Earnings
Upcoming earnings announcement for Prime Medicine
Date
Thursday, May 7, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.25
Revenue Estimate
$1.1M
Earnings History
Past 12 earnings reports for Prime Medicine
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Q4 2025 | -$0.24Est: -$0.25 | +4.0% | $838.0KEst: $2.2M | -61.1% |  10-K |
| Nov 7, 2025 | Q3 2025 | -$0.32Est: -$0.23 | -39.1% | $1.2MEst: $4.2M | -71.2% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.41Est: -$0.35 | -17.1% | $1.1MEst: $2.9M | -61.6% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.40Est: -$0.31 | -29.0% | $1.5MEst: $3.4M | -57.6% | 10-Q |
| Feb 28, 2025 | Q4 2024 | -$0.31Est: -$0.37 | +16.2% | $2.2M | — | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.44Est: -$0.39 | -12.8% | $209.0K | — | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.46Est: -$0.41 | -12.2% | -Est: $1.6M | -100.0% | 10-Q |
| May 10, 2024 | Q1 2024 | -$0.44Est: -$0.47 | +6.4% | $591.0K | — | 10-Q |
| Mar 1, 2024 | Q4 2023 | -$0.72Est: -$0.51 | -41.2% | - | — | 10-K |
| Nov 3, 2023 | Q3 2023 | -$0.55Est: -$0.46 | -19.6% | - | — | — |
| Aug 7, 2023 | Q2 2023 | -$0.47Est: -$0.42 | -11.9% | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.44Est: -$0.42 | -4.8% | - | — | — |